Bio-Path Holdings, Inc. (NASDAQ:BPTH)’s share price was down 3.3% during trading on Monday . The stock traded as low as $0.29 and last traded at $0.31. Approximately 1,714,400 shares changed hands during trading, an increase of 333% from the average daily volume of 395,857 shares. The stock had previously closed at $0.30.

Several equities analysts have recently commented on BPTH shares. HC Wainwright restated a “buy” rating on shares of Bio-Path Holdings in a report on Thursday, July 20th. ValuEngine cut shares of Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

Bio-Path Holdings (NASDAQ:BPTH) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.02). equities research analysts predict that Bio-Path Holdings, Inc. will post -0.08 EPS for the current fiscal year.

A number of large investors have recently modified their holdings of BPTH. Bank of New York Mellon Corp boosted its holdings in Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after purchasing an additional 5,172 shares in the last quarter. Legal & General Group Plc boosted its holdings in Bio-Path Holdings by 5,474.3% in the second quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after purchasing an additional 1,741,978 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Bio-Path Holdings by 0.3% in the second quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock worth $492,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Sabby Management LLC boosted its holdings in Bio-Path Holdings by 73.2% in the second quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock worth $462,000 after purchasing an additional 503,488 shares in the last quarter. Hedge funds and other institutional investors own 15.15% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Bio-Path Holdings, Inc. (BPTH) Stock Price Down 3.3%” was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/11/13/bio-path-holdings-inc-bpth-stock-price-down-3-3.html.

About Bio-Path Holdings

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.